^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy
Excerpt:
Herein, we report the case of a patient with DLBCL having TP53 mutation who showed progression following four cycles of rituximab-based immunochemotherapy but achieved sustained partial remission following chidamide-based chemotherapy.
Secondary therapy:
Chemotherapy
DOI:
10.2217/imt-2018-0083
Source:
Title:
Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy
Excerpt:
In vitro experiments performed using the DLBCL cell lines OCI-ly1 (LY1; mutant TP53)...demonstrated that chidamide is more potent against cells with mutant TP53 mutant than those with wild-type TP53.
DOI:
10.2217/imt-2018-0083
